JavaScript seems to be disabled in your browser. You must have JavaScript enabled in your browser to utilize the functionality of this website.
There are no items in your shopping cart
Featured Products
Axon 2556
CAS [1072833-77-2]
MF C14H19BCl2N2O4MW 361.03
Selective and reversible inhibitor of the β5 subunit sites of the 20S proteasome with antitumor activity in various malignancies. MLN2238 exhibits improved pharmacodynamics and antitumor activity compared with bortezomib in various B-cell lymphoma models, due to a greater tumor to blood ratio of proteasome inhibition that ultimately translates into improved tumor pharmacodynamic response and antitumor activity in several tumor xenograft models.
MLN2238 is also available as the more stable citrate prodrug MLN9708 (Axon 2557).
KEYWORDS: MLN2238 | supplier | Proteasome inhibitor | Ixazomib | MLN-2238 | CAS [1072833-77-2] | Ubiquitin | Proteasome 20S | Inhibitor | β5 subunit | B-cell lymphoma | FDA approved | MLN 9708
(R)-1-(2-(2,5-dichlorobenzamido)acetamido)-3-methylbutylboronic acid
[1072833-77-2]
The purity of Axon Ligands™ is confirmed by HPLC-MS, 1H-NMR and/or microanalysis. Analytical data are available upon request.
Caution: Axon Ligands™ are not fully tested. They are for research purposes only! Not for human consumption!
* Required Fields